RIGL News

Rigel Provides Business Update and 2026 Outlook

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Ongoing Global Trials and Promising Candidates Like Sovleplenib Create Strong Investment and Innovation Opportunities

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update